2023
Orbitofrontal cortex microRNAs support long-lasting heroin seeking behavior in male rats
Zanda M, Floris G, Daws S. Orbitofrontal cortex microRNAs support long-lasting heroin seeking behavior in male rats. Translational Psychiatry 2023, 13: 117. PMID: 37031193, PMCID: PMC10082780, DOI: 10.1038/s41398-023-02423-4.Peer-Reviewed Original ResearchConceptsOpioid use disorderOrbitofrontal cortexHL animalsHeroin seekingDrug cravingSelf-administer heroinLong-term heroinMaintenance of abstinenceDrug seeking behaviorOpioid useHeroin cravingMale ratsPreclinical studiesUse disordersDrug useExposure paradigmBrain regionsAbstinence periodAbstinenceHeroinDrug cuesSeeking behaviourLow dosageCravingProteomic analysis
2013
Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation
Chakkera HA, Chang Y, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings 2013, 45: 137-141. PMID: 23375287, DOI: 10.1016/j.transproceed.2012.10.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cohort StudiesFemaleGenetic VariationHumansImmunosuppressive AgentsIndians, North AmericanKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideTacrolimusTime FactorsConceptsKidney transplant recipientsTrough levelsTacrolimus dosingTransplant recipientsSingle nucleotide polymorphismsDaily tacrolimus doseLower tacrolimus dosesTacrolimus pharmacokinetic parametersTacrolimus trough levelsCaucasian kidney transplant recipientsStable dosesTacrolimus doseKidney transplantationTacrolimus dosesTacrolimus pharmacokineticsMonths posttransplantationOral clearanceTacrolimus clearanceDrug eliminationPharmacokinetic parametersVariant single nucleotide polymorphismsTacrolimusDrug metabolismPharmacokinetic studyLow dosage
1995
Periconceptional folic acid and neural tube defects: public health issues.
Pérez-Escamilla R. Periconceptional folic acid and neural tube defects: public health issues. Bulletin Of The Pan American Health Organization 1995, 29: 250-63. PMID: 8520610.Peer-Reviewed Original ResearchConceptsNeural tube defectsFolic acid supplementationPublic health issueAcid supplementationUnfavorable benefit/risk ratioPericonceptional folic acid intakeTube defectsBenefit/risk ratioRecurrent neural tube defectsHealth issuesFolic acidFolic acid intakePericonceptional folic acidDietary counselingPrimary preventionAcid intakeNTD pregnanciesRisk ratioProtective effectLow prevalenceFood fortificationMedical guidanceLow dosagePericonceptionSupplementation
1990
Behavioral Side Effects of Fluoxetine in Children and Adolescents
RIDDLE M, KING R, HARDIN M, SCAHILL L, ORT S, CHAPPELL P, RASMUSSON A, LECKMAN J. Behavioral Side Effects of Fluoxetine in Children and Adolescents. Journal Of Child And Adolescent Psychopharmacology 1990, 1: 193-198. DOI: 10.1089/cap.1990.1.193.Peer-Reviewed Original ResearchBehavioral side effectsSide effectsObsessive-compulsive symptomsExacerbation of symptomsCompulsive symptomsCommon psychopathological symptomsNeurological statusDosage reductionComplete resolutionSleep disturbancesMotor restlessnessLow dosesUnwanted symptomsFluoxetineSymptomsSubjective sensationPsychopathological symptomsLow dosageAge 8ChildrenDosesRestlessness
1985
Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia
Roberts JD, Ershler WB, Tindle BH, Stewart JA. Low‐dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer 1985, 56: 1001-1005. PMID: 3860278, DOI: 10.1002/1097-0142(19850901)56:5<1001::aid-cncr2820560504>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsLow-dose cytosineAcute myelogenous leukemiaMyelodysplastic syndromeMyelogenous leukemiaTransient hematologic toxicityPeripheral blood countsAppropriate clinical roleTransfusion requirementsHematologic toxicityPartial responseDecreased incidenceBlood countClinical roleLow dosagePatientsSyndromeLeukemiaInfectionIncidenceCessation
1983
The choice of contrast agent for myelography in patients with nonpenetrating cervical spine trauma.
Virapongse C, Wagner F, Sarwar M, Kier E. The choice of contrast agent for myelography in patients with nonpenetrating cervical spine trauma. Radiology 1983, 147: 467-71. PMID: 6836124, DOI: 10.1148/radiology.147.2.6836124.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply